A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis.

This document provides information about a Phase 3 clinical trial investigating the use of Dupilumab in the treatment of prurigo nodularis (PN) in children and adolescents. The trial aims to assess the concentration of Dupilumab in the blood over time and the occurrence of any adverse events or anti-drug antibodies. The trial is not yet recruiting and plans to enroll 18 participants, with an estimated completion date of November 3, 2027. The trial is being conducted by Sanofi in collaboration with Regeneron Pharmaceuticals, with Sanofi being the responsible party. [Extracted from the article]